Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06892431

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

A Phase II Clinical Study of JMT101 Injection Combined With Mitoxantrone Liposome Injection in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Cancer Who Have Failed At Least Two Prior Lines of Treatment

Sponsor: Shanghai JMT-Bio Inc.

Conditions Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy Recurrent or Metastatic Nasopharyngeal Cancer

Interventions Capecitabine Docetaxel injection Gemcitabine hydrochloride for injection JMT101 injection Mitoxantrone Hydrochloride Liposome

Updated 1 time since 2025 Last updated: Mar 23, 2025 Started: Apr 1, 2025 Primary completion: Dec 31, 2025 Completion: Apr 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy and Recurrent or Metastatic Nasopharyngeal Cancer and is currently actively recruiting participants. Shanghai JMT-Bio Inc. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai JMT-Bio Inc.

Data source: Shanghai JMT-Bio Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.